Expression of ASNS has been implicated in resistance to the important anti-leukemic therapy ASNase [15, 19–22], which has been in clinical use for decades to treat ALL, and thus we selected the hit ASNS for follow-up studies given the potential clinical relevance in using APR-246 as a novel strategy to overcome ASNase resistance in this disease. This evidence concerns the gene ASNS and acute lymphoblastic leukemia.